Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease.

ABSTRACT:

Background

A recent trial involving predominantly Caucasian subjects with Parkinson Disease (PD) showed switching overnight from an oral dopaminergic agonist to the rotigotine patch was well tolerated without loss of efficacy. However, no such data have been generated for Korean patients.

Methods

This open-label multicenter trial investigated PD patients whose symptoms were not satisfactorily controlled by ropinirole, at a total daily dose of 3 mg to 12 mg, taken as monotherapy or as an adjunct to levodopa. Switching treatment from oral ropinirole to transdermal rotigotine was carried out overnight, with a dosage ratio of 1.5:1. After a 28-day treatment period, the safety and tolerability of switching was evaluated. Due to the exploratory nature of this trial, the effects of

SUBMITTER: Kim HJ 

PROVIDER: S-EPMC3166898 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature